Comment
doi: 10.7326/J22-0009.
Epub 2022 Mar 1.
In type 2 diabetes with increased CV risk, tirzepatide reduced HbA1c vs. glargine at 52 wk
Affiliations
- PMID: 35226523
- DOI: 10.7326/J22-0009
Item in Clipboard
Comment
In type 2 diabetes with increased CV risk, tirzepatide reduced HbA1c vs. glargine at 52 wk
Ann Intern Med.
2022 Mar.
Abstract
Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398:1811-24. 34672967.
Comment on
-
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.Lancet. 2021 Nov 13;398(10313):1811-1824. doi: 10.1016/S0140-6736(21)02188-7. Epub 2021 Oct 18. Lancet. 2021. PMID: 34672967 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
